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Introduction
The sepsis is a leading, infectious complication among 
critically ill patients and represents a substantial health 
care burden [1]. It is the combination of pathologic in-
fection and physiological changes collectively known 
as the systemic inflammatory response syndrome [2]. 
The incidence of sepsis and the number of sepsis-related 
deaths are increasing, and is now among the 10 leading 
causes of death in the Unites States with > 700,000 cases 
per year and with a mortality rate of around 29% [3]. 
Recent data have estimated that the incidence rate for 
severe sepsis lies between 50 and 100 cases per 100,000 
individuals among industrialized countries [4].
The diagnosis is made on the basis of the presence of 
inflammatory response indicators in the setting of sus-
pected or confirmed infection. The sepsis syndromes are 
a continuum of a disease process progressing from sep-
sis (infection with an inflammatory response) to severe 
sepsis (sepsis with organ dysfunction) to septic shock 
(sepsis with tissue hypoperfusion) [3].
Possible reasons of the increased incidence of sepsis in-
clude massive use of invasive procedures and immuno-
suppressive drugs, chemotherapy, and transplantation; 
the spread of human immunodeficiency virus (HIV) in-
fection and increasing microbial resistance [5].
Coagulase-negative Staphylococci (CoNS), Staphyloco-
ccus aureus (S. aureus), Enterococcus sp., Gram-neg-
ative bacilli and Candida sp. represent the most com-
monly isolated pathogens in these infections [6].
However, the microbiology of sepsis has changed over 
time. Although in the past gram negative organisms were 
most commonly implicated, increasingly gram-positive 
organisms are isolated [7], such that roughly similar 
numbers of gram-positive and gram-negative organisms 
are now associated with sepsis. Sepsis can also be caused 
by a fungal or parasitic infection, and no infectious agent 
is identified in about one-third of patients [8].
Patients with a history of cancer are at increased risk 
for acquiring and subsequently dying from sepsis, com-
pared to the general population, although incidence and 
fatality rates are decreasing over time [9].
It is clinically difficult to recognize sepsis because signs 
and symptoms are often non-specific. Fever is a known 
cardinal sign of sepsis and has been for many years con-
sidered a harmful effect and widely treated with antipy-
retic agents. The possible infectious origin of fever is 
a key point in the management of neutropenic patients. 
Indeed, febrile neutropenia is associated with reduced 
survival, due not only to the infectious complications, 
but also to other factors, including chemotherapy dose-
delays and reductions [10]. Prompt diagnosis of infec-
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Summary
Introduction. Sepsis is a major cause of significant morbidity and 
mortality in neutropenic patients. Blood culture remains the gold 
standard in the microbiological diagnosis of bacterial or fungal 
bloodstream infections, but it has clear limits of rapidity and sen-
sitivity. The objective of the study was to compare the real-time 
polymerase chain reaction (RT-PCR) with automated blood cul-
tures (BC) method in detection in whole blood of pathogens in 
febrile neutropenic patients with hematological malignancies.
Methods. A total of 166 consecutive febrile neutropenic patients 
were enrolled. Blood samples for cultures and SeptiFast testing 
were obtained at the onset of fever, before the implementation of 
empirical antibiotic therapy. 
Results. Forty (24.1%) samples out of the 166 blood samples 
tested, were positive by at least one method. Twenty-three (13.9%) 
samples were positive by blood culture and 38 (22.9%) by multi-
plex real-time PCR. The analysis of concordance evidenced a low 
correlation between the two methods (n = 21; 52.5%), mainly due 
to samples found negative by culture but positive with the Septi-
Fast assay. Sensitivity, specificity, and positive and negative pre-
dictive values of RT-PCR were 91.3%, 88.1%, 55.3%, and 98.4%, 
respectively, compared with BC.
Discussion. Multiplex real-time PCR assay improved detection of 
the most bacteria associated with febrile neutropenia episodes. Fur-
ther studies are needed to assess the real advantages and clinical 
benefits that molecular biology tests can add in diagnosis of sepsis.
The full article is free available on www.jpmh.org 
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tion in febrile neutropenia patients with hematological 
malignancy is essential for choosing the appropriate 
therapeutic strategy.
Blood culture remains the gold standard for diagnosing 
microbial pathogens in the blood, but that has clear lim-
its of rapidity and sensitivity [11].
Aim of the study was to compare the real-time polymer-
ase chain reaction (RT-PCR) with automated blood cul-
tures (BC) method in detection in whole blood of patho-
gens most frequently responsible for infections of the 
bloodstream in febrile neutropenic patients with hema-
tological malignancies.
Methods 
Patients and specimens. A total of 166 consecutive 
febrile neutropenic patients (median age 66.1 years, 
range 23-82 years; 103 males and 63 females) were en-
rolled between January 2010 and December 2010. All 
patients were admitted to the Hematology Department, 
Hospital “G. Panico”, Tricase, Italy. The blood sam-
ples were drawn from febrile (temperature > 38.0°C) 
neutropenic patients with a neutrophil count below 
< 0,5 x 109 L-1 in presence of acute and/or chronic blood 
disorders or bone marrow transplant. Blood samples 
for cultures and SeptiFast testing were obtained at the 
onset of fever, before the implementation of empiri-
cal antimicrobial therapy. Febrile episodes in these pa-
tients were therapeutically managed at the physician’s 
discretion on the basis of the suspected etiology, local 
microorganism resistance patterns and the severity of 
illness.
Cultural methods. Blood cultures were done using the 
Automated BacT/Alert 3D (bioMérieux, France) con-
tinuous-monitoring blood culture system, following 
the instructions of the manufacturer. 10 ml of periph-
eral venous blood were collected from patients, and im-
mediately inoculated into two bottles BacT/Alert (bi-
oMérieux, France), one for aerobic microorganisms and 
one for anaerobes. The bottles were then processed in 
a BacT/Alert 3D automated blood culture system, with 
monitoring of carbon dioxide production within each 
bottle every 10 min 24 h per day. From 8 am to 7 pm, 
all bottles signalled as positive were removed from the 
instrument, and an aliquot was taken for Gram stain and 
culture on solid media for subsequent analysis. Identi-
fication and determination of sensitivity to antibiotics 
were performed with the VITEK 2 system (bioMérieux, 
France).
Molecular methods. For each sample, 1.5 ml K-EDTA-
treated uncultured blood was processed by the commer-
cial real-time PCR test LightCycler SepstiFast (Roche 
Molecular System Branchburg, NJ, USA). LightCycler 
SeptiFast Test is an assay capable of detecting a wide 
range of bacterial and mycotic pathogens (Tab. I).
The LightCycler SeptiFast MGRADE test was per-
formed on blood samples, as described in several recent 
publications [12, 13].
Results
Forty (24.1%) samples out of the 166 blood samples 
tested were positive by at least one method. Twenty-
three (13.9%) samples were positive by blood culture 
and 38 (22.9%) by multiplex real-time PCR (Tab. II). 
The analysis of concordance evidenced a low correlation 
between the two methods (n = 21; 52.5%), mainly due to 
samples found negative by culture but positive with the 
SeptiFast assay. Conversely, only 2 out of 23 samples 
positive by blood culture (8.7%) were negative by real-
time PCR (Tab. II).
Sensitivity, specificity, and positive and negative pre-
dictive values of RT-PCR were 91.3%, 88.1%, 55.3%, 
and 98.4%, respectively, compared with BC.
Gram-negative bacteria were the most frequently isolat-
ed pathogens (n = 27; 67.5%), followed by Gram-posi-
tive (n = 9; 22.5%) and fungi (n = 4; 10.0%) (Tab. III).
Only for some species (CoNS, Escherichia coli, Serra-
tia marcescens and Candida parapsilosis) high concord-
ance of methods was found; while for all other species 
only SeptiFast was able to detect the presence of patho-
gens in blood samples (Tab. III).
Tab. I. list of pathogen detectable by lightCycler septiFast test.
Gram-positive bacteria Gram-negative bacteria Fungi
staphylococcus aureus escherichia coli Candida albicans
Coagulase-negative staphylococci Klebsiella pneumoniae/oxytoca Candida tropicalis
staphylococcus hominis serratia marcescens Candida krusei
staphylococcus epidermidis enterobacter cloacae/aerogenes Candida glabrata
streptococcus pneumoniae proteus mirabilis Candida parapsilosis
streptococcus spp pseudomonas aeruginosa aspergillus fumigatus
streptococcus pyogenes acinetobacter baumannii
streptococcus agalactiae stenotrophomonas maltophilia
streptococcus mitis
enterococcus faecium
enterococcus faecalis
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Only in one case, repeated measurements by cultural 
method were negative for Aspergillus fumigatus but 
positive by molecular method.
Discussion
All patients with hematologic malignancies undergo-
ing intensive cytotoxic chemotherapy causing long-term 
granulocytopenia are at high risk of infectious complica-
tions [9].
In recent decades, the management of severe neutropenic 
patients has significantly improved in both the prognosis 
and the antimicrobial treatment [14], while the etiologi-
cal diagnosis is still mainly based on blood culture.
Due to the low sensibility and specificity of convention-
al method to diagnose the sepsis, the need for new more 
rapid and effective techniques became more urgent.
In recent years, the incidence of sepsis is increasing 
and the diagnosis in neutropenic patients and, more 
generally immunocompromised, remains a challenge 
as approximately half of sepsis cases are culture nega-
tive [15].
The increased incidence of the invasive fungal infec-
tions and of the infections caused by CoNS, as a re-
sult of the widespread use of vascular catheters, and 
the antimicrobial prophylaxis, are all factors that limit 
the ability of blood cultures to identify the causative 
agent of bloodstream infections in onco-hematological 
patients. 
The delay or failure in diagnostic procedures lead to in-
adequate treatment in 25% of cases, with a significantly 
increased risk of death [16]. The autopsy confirmed 
that a misdiagnosis along with inadequate antimicrobial 
treatment is the most preventable cause of death due to 
sepsis.
Moreover, an inappropriate antibiotic therapy seem to 
be an important determinant of hospital mortality, as it 
may cause side effects and antibiotic resistance as well 
as increased costs of treating patients [17-19].
Tab. II. Comparison of results from the lightCycler septiFast test and Bact/alert blood culture system in the cohort patients (n = 45/166) 
studied.
LightCycler
SeptiFast Test
BacT/Alert blood
culture system
Total no. of 
sample (%)
Positive samples
No. (%)
Negative samples
no. (%)
positive samples (%) 21 (12.7) 17 (10.2)  38 (22.9)
Negative samples (%) 2 (1.2) 126 (75.9) 128 (77.1)
Total (%) 23 (13.9) 143 (86.1) 166 (100)
Tab. III. microorganisms positive (n = 40) detected by blood cultures and septiFast assay.
Blood cultures
n. (%)
LightCycler 
SeptiFast Test
n. (%)
Both
assays
n.
Gram-positive
staphylococcus aureus 0 (0.0) 3 (7.9) 3
Coagulase-negative staphylococci 0 (0.0) 1 (2.6) 1
staphylococcus hominis 3 (13.0) 3 (7.9) 3
staphylococcus epidermidis 1 (4.3) 1 (2.6) 1
staphylococcus (other types) 1 (4.3) 0 (0.0) 1
Gram-negative
enterobacter cloacae 1 (4.3) 2 (5.3) 2
escherichia coli 5 (21.7) 5 (13.2) 5
Klebsiella pneumoniae 0 (0.0) 3 (7.9) 3
acinetobacter baumannii 0 (0.0) 1 (2.6) 1
proteus mirabilis 0 (0.0) 1 (2.6) 1
serratia marcescens 5 (21.7) 5 (13.2) 5
stenotrophomonas maltophilia 0 (0.0) 1 (2.6) 1
pseudomonas aeruginosa 5 (21.7) 8 (21.1) 8
Burkholderia cepacia 1 (4.3) 0 (0.0) 1
Fungi
aspergillus fumigatus 0 (0.0) 1 (2.6) 1
Candida albicans 0 (0.0) 1 (2.6) 1
Candida krusei 0 (0.0) 1 (2.6) 1
Candida parapsilosis 1 (4.3) 1 (2.6) 1
Total 23 (57.5) 38 (95.0) 40 (100)
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The results of blood cultures, generally, don’t allow to 
start a correct antibiotic therapy because they are not 
available as soon as necessary.
Indeed, blood culture typically becomes positive 8-36 h 
after sampling, and therapy can then be adapted and 
based on presumptive bacterial identification suggested 
by Gram-stain characteristics. A more precise pathogen 
identification and susceptibility profile, however, is not 
available until up to 24-48 h [20, 21].
An important retrospective study showed that during se-
vere sepsis effective antimicrobial administration within 
the first hour is associated with increased survival [22].
One of the most promising approaches for diagnosis of 
blood infections seems to be directly based on the iden-
tification of bacterial and fungal DNA in whole blood by 
PCR assays [12].
Overall, according to our data multiplex real-time PCR 
assay improved detection of the most bacteria asso-
ciated with febrile neutropenia episodes. Results are 
similar to the previous reports comparing the lightCy-
cler SeptiFast assay with the conventional blood cul-
tures [9, 12, 13, 24].
However, although most episodes of febrile neutropenia 
are assumed to be caused by an infection, the incidence 
of proven bloodstream infections in febrile neutropenia is 
only ~30% based on results of blood cultures [25, 26].
Recent studies reporting a higher yield of positive re-
sults by various PCR-based methods to detect bacterial 
and fungal DNA have yet to be validated in larger co-
horts [12, 27].
There is a limitation in order to PCR test used for iden-
tification of bacteria and fungi from whole blood speci-
mens; in fact it is impossible to collect simultaneously 
data on the isolated pathogen and its antibiotic suscep-
tibility.
The antibiotic resistant marker genes that can be iden-
tified by molecular biological methods are rapidly in-
creasing; many of these can be identified routinely, such 
as mecA gene for methicillin resistance in S. aureus and 
rpoB/katG/inga for resistance to rifampicin/isoniazid in 
M. tuberculosis.
However, the detection of all the genes of resistance, 
evaluated in more than a hundred, would require a large 
number of tests for each sample.
Despite the advantages of the SeptiFast method, the 
blood culture remains an important diagnostic tool that 
provides essential information regarding the antibiotic 
resistance of microorganisms. Therefore, blood culture 
and real-time PCR methods are not interchangeable but 
should be applied in combination to get a correct diag-
nosis.
In conclusion, it is obvious that the blood culture re-
mains the reference method for diagnosis of sepsis, al-
lowing the detection of bacteria and fungi responsible 
of infection and the evaluation of antibiotics susceptibil-
ity. However, the simultaneous application of molecu-
lar techniques such as the SeptiFast with blood cultures 
could provide a valuable contribution to the clinician 
because of the rapidity of testing (6 hours), to detect co-
infections or slow growing organisms, and to the ability 
to isolate pathogens even in patients receiving prophy-
lactic/antibiotic therapy.
However, further studies are needed to assess the real 
advantages and clinical benefits that molecular biology 
tests can add in diagnosis of sepsis, especially in neutro-
penic patients with onco-hematological cancers. 
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